We investigated the outcomes of postmenopausal women with hormone receptor-positive, early breast cancer with special histotypes (mucinous, tubular, or cribriform) enrolled in the monotherapy cohort of the BIG 1-98 trial.
with similar biological features and stages [4] . In particular, within luminal breast cancer, several special histotypes display an extremely good prognosis, often approaching or equaling that of the general population [5, 6] . Histotypes with good prognosis include: pure tubular carcinoma, a rare histology accounting for <2% of invasive breast cancer and with an excellent prognosis [7, 8] ; cribriform carcinoma, which also has a very favorable prognosis irrespective of lymph node metastases [8, 9] ; and pure mucinous breast carcinoma, representing 1%-4% of all breast cancers. If present in pure form, this histotype predicts a 10-year survival >90% [10, 11] .
Limited results are available on the outcomes of these rare histotypes according to the adjuvant treatment received. Consequently, no information from retrospective analyses is available for tailoring adjuvant treatment of an individual patient with these special histotypes.
We investigated the outcomes of postmenopausal women with hormone receptor-positive (HR+), early invasive breast cancer with special tumor histotypes (mucinous, tubular, or cribriform) who were enrolled in the monotherapy cohort of the BIG 1-98 trial, and the relationship between outcomes and other biological or treatment characteristics.
patients and methods
The design and conduct of the BIG 1-98 trial have been described elsewhere [12, 13] .
This analysis was based on the BIG 1-98 at 8.7 years median follow-up [14] . The analytic cohort for this analysis included women randomized to 5 years of tamoxifen or letrozole monotherapy whose tumors were centrally reviewed (n = 4091) ( Figure 1 ). Histotypes considered in this analysis were mucinous (n = 87) or mucinous variant (n = 13), tubular (n = 71), or tubular variant (n = 3), and cribriform pure (n = 4) or mixed (n = 5) [15] . Mucinous and mucinous variants were combined into the 'mucinous' group, and tubular and cribriform types were combined into the 'tubular/cribriform' group ( Figure 1 ). The histotypes studied included 183 patients with either mucinous or tubular/cribriform tumors, 4.4% of the analytic cohort. Ninetysix women were randomized to letrozole and 87 to tamoxifen. Comparator histologic groups were ductal and other histotypes: 406 with lobular histology, 234 with other classifications, and 11 with missing histology. Luminal A was defined as HR+, HER2-negative, and Ki-67 <14%; luminal B as HR+, HER2-negative, and Ki-67 ≥14% [16] .
The tamoxifen group included 24 women (28%) who selectively crossed over to letrozole after the first interim efficacy results of the trial were released in 2005. Follow-up for these women was censored at the time of the selective crossover, reducing the median follow-up of the special histotype group (n = 183) to 8.1 years. No outcome events were lost as a result of the censoring.
All participants provided written informed consent. Ethics committees and relevant health authorities approved the protocol.
statistical analysis
All patients were analyzed according to randomized treatment. Comparisons of baseline disease, demographic, and prior treatment characteristics used Fisher's exact test for categorical variables and Wilcoxon rank-sum or Kruskal-Wallis tests for continuous characteristics. Four time-to-event outcomes are presented: disease-free survival (DFS), overall survival (OS), breast cancer-free interval (BCFI), and distant recurrence-free interval (DRFI).
DFS was defined as the time from randomization to the earliest invasive breast recurrence, new invasive breast cancer in the contralateral breast, any second (nonbreast) malignancy, or death from any cause. OS was defined as the time from randomization to death from any cause. BCFI was defined as the time from randomization to the earliest invasive breast recurrence or new invasive breast cancer in the contralateral breast. DRFI was defined as the time from randomization to the earliest distant metastases. For BCFI and DRFI, deaths without prior cancer events were censored. Comparisons of survival distributions were made using the log-rank test. Cox proportional hazards (PH) models, stratified by randomization option (two-arm/fourarm) and chemotherapy, were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Univariate Cox PH models included only treatment as a predictor.
Multivariable Cox PH models were fit to each outcome to assess important predictors. Candidate predictors in each model were: histology, tumor grade and size, subtype (luminal A or B, missing/other ER+), nodal status (N0/Nx, N+), and local therapy as the combination of radiotherapy (RT) and either mastectomy (MTX) or breast-conserving surgery (BCS) (BCS/RT, BCS/no RT, MTX/RT, MTX/no RT Distributions and 5-year Kaplan-Meier estimates of outcomes for the four histology groups are summarized in Figure 2 . Overall, women with tubular/cribriform tumors showed the best outcomes compared with those in the other three histologic groups. Women with mucinous carcinoma had comparable DFS and OS to women with ductal or other histotypes. Five-year recurrence rates were higher in patients with tubular/cribriform (97.5%) or mucinous (93.5%) disease than in patients with ductal (88.9%) or other histotypes 89.9%, P = 0.03). Women with mucinous or tubular/cribriform carcinoma had better DRFI (5-year DRFI: 97.8%, 98.8%, respectively) than those with ductal (90.9%) or other (92.1%) (P = 0.002) carcinomas.
outcome according to treatment (letrozole versus tamoxifen)
The median age at randomization was 65 and 64 years in the letrozole and tamoxifen arms, respectively. Women assigned to tamoxifen more often had N0/Nx disease (82% tamoxifen, 71% letrozole) or grade 1 tumors (76% tamoxifen, 66% letrozole). A lower percentage of patients in the tamoxifen group received neoadjuvant or adjuvant chemotherapy (3% tamoxifen, 11.5% letrozole); however, none of these differences were statistically significantly different.
The 5-year DFS estimates (±standard error of the estimate) were 83.2 ± 3.8% for patients in the letrozole group versus 94.9 ± 2.5% for those in the tamoxifen group ( Figure 3A) , whereas the 5-year OS estimates were 93.7 ± 2.5% versus 97.3 ± 1.9% ( Figure 3B ). Among patients receiving tamoxifen, the only distant recurrence occurred at ∼72 months of followup. As a result, 5-year estimates of DRFI were 100% in the tamoxifen group and 96.8 ± 1.8% in the letrozole group ( Figure 3C ). No recurrences were reported for the first year of follow-up in either treatment group.
When the effect of treatment upon outcomes was evaluated by univariate models, only BCFI showed a difference between letrozole and tamoxifen: the hazard of recurrence was 3.3 times higher among women receiving letrozole and was marginally significant [HR (letrozole versus tamoxifen) 3.31, 95% CI 0.94-11.7, P = 0.06]. This finding was upheld by the multivariable Cox PH model [HR (letrozole versus tamoxifen) 3.54, 95% CI 0.96-13.1, P = 0.06].
The sites of first recurrence were: local-regional and contralateral in 6.3% of patients in the letrozole group and 2.2% in the tamoxifen group; distant in 4.1% in the letrozole group and 1.1% in the tamoxifen group.
outcomes according to treatment and histotype
The relative effects of letrozole and tamoxifen were investigated according to the two histologic groups (mucinous versus tubular/ cribriform). Looking at the four histotype-treatment combinations, patients with mucinous carcinoma treated with letrozole appeared to have the worst outcomes. In contrast, outcomes for patients with mucinous carcinoma treated with tamoxifen were similar to that of patients with tubular/cribriform, suggesting that, in these histotypes, the benefit of letrozole over tamoxifen is less clear than in ductal or other histologies (supplementary Figure S1 , available at Annals of Oncology online). However, the HR (letrozole versus tamoxifen) did not reach statistical significance for any of the four outcomes considered ( Table 2) .
comparisons of treatment effects for histotype
The forest plot summarizes the effects of treatment overall and in each of four subgroups based on univariate models (Figure 4) . Overall, letrozole has significantly greater efficacy than tamoxifen for all four end points. The superiority of letrozole is less clear in the rare histotypes. The HR estimates tend to favor tamoxifen for all four end points in the mucinous and tubular/cribriform groups, but the CIs are too wide to draw any conclusions favoring tamoxifen.
discussion
The present analysis provides an opportunity to study very rare histotypes that have been centrally evaluated and treated and followed uniformly within a large clinical trial. Others have reported the favorable prognosis of these histotypes, but there are no published reports about differential benefits of endocrine therapy.
Our report suggests that mucinous, tubular, and cribriform histotypes have a more favorable prognosis compared with [17] . Likewise, in a series of 102 patients, none of the patients with tubular carcinoma developed distant metastasis or died from breast cancer [18] . The survival of patients with tubular carcinoma is similar to the general population, and there is no evidence that adjuvant therapy influences survival, even if sentinel node biopsy is positive [19] . Tubular carcinoma also has a favorable long-term prognosis, even if axillary nodes were involved; thus, nodal status may not be an indicator of poor outcome [20] . Our results also suggest that tamoxifen may be a treatment choice for women with these histotypes. The overall benefit of letrozole over tamoxifen observed in ductal or other histologies was not as strong in the special histotypes, although based on a limited number of events. Patients with mucinous carcinoma treated with letrozole had the worst outcome among the groups studied. In contrast, outcomes for patients with mucinous disease who were treated with tamoxifen were similar to those with tubular/cribriform breast cancer. Side-effect profile and patient preference should guide the choice of adjuvant endocrine treatment of women with these histologies.
It should be noted that patients in our study with special histotypes had lower risk characteristics (72% had luminal A). Mucinous, tubular, and cribriform histotypes are found among luminal A cancers more than in other histotypes [16, 21] . In our series, patients with tubular and cribriform histotypes were more frequently classified as luminal A, while patients with mucinous breast cancer had a greater proportion with luminal B (HER2-negative). The lower risk disease in our study sample contributed to small numbers of outcome events, especially for BCFI or DRFI, which could influence the power of our multivariable models to find factors associated with outcome.
Adjuvant therapy with aromatase inhibitors provides, on average, superior outcomes to tamoxifen for postmenopausal women with endocrine-responsive early breast cancer; however, data from BIG 1-98 suggest that, in low-proliferating tumors, the magnitude of letrozole benefit versus tamoxifen might not be as large as in more highly proliferative tumors [22, 23] , thus suggesting a similar treatment benefit in luminal A tumors. In general, in the current analysis, patients with rare histologies and luminal B (HER2-negative) disease had a threefold increase in the hazard of death compared with luminal A disease. One possible explanation of the better outcome of these histotypes may be found in their genomic expression. Cribriform and tubular carcinomas usually display similar immunophenotypes and are characterized by similar types and patterns of genetic aberrations, commonly found in most low-grade luminal-type breast carcinomas [10, 24, 25] . However, significant differences were detected and validated by quantitative reverse transcriptase PCR, which may in part explain the reported, more favorable outcome of cribriform/tubular [8] . Some authors also suggest that tubular and cribriform carcinomas have similar clinical presentation, natural history, and are probably associated with the same family of precursor and preinvasive lesions [5, 26] , thus indicating a common etiological background or the involvement of common genetic pathways during carcinogenesis [25] .
In conclusion, patients with rare histologies treated with 5 years of letrozole or tamoxifen in the BIG1-98 trial had better outcomes than other histologies. The magnitude of the letrozole advantage compared with tamoxifen seen in the overall population was not observed in patients with mucinous or tubular/cribriform disease. For these rare histologies, our data suggest that tamoxifen could be a reasonable treatment option.
acknowledgements
We thank to women, pathologists, physicians, nurses and data managers who participated in the BIG 1-98 clinical trial. 
